Global Migraine Drug Forecast and Market Analysis Report 2021-2030: Gepants are the Most Promising New Entrants to the Migraine Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Migraine - Global Drug Forecast and Market Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.

The migraine market in the 7MM was valued at $4.7B in the 2020 baseline year. The publisher anticipates that over the 10-year forecast period, the market is projected to grow at a Compound Annual Growth Rate (CAGR) of 9.9%, reaching $12.0B by 2030.

Migraine is a complex neurological condition characterized by frequent headaches that can last between four and 72 hours. The pain is often unilateral and pulsating in nature, which can often be worsened by physical activity. In most cases, migraine is associated with symptoms such as photophobia, phonophobia, osmophobia, nausea, vomiting, loss of appetite, and sometimes sensory disturbances.

The two clinically and commercially relevant segments considered for the classification of migraine in this report are patients with episodic migraine, who suffer up to 14 migraines per month, and patients with chronic migraine, who suffer 15 or more attacks per month.

For patients that experience four or more migraine attacks per month, physicians look to prescribe a preventive treatment. Preventive treatment is considered an additive to acute therapy and minimizes the risk of medication overuse headaches associated with Nonsteroidal anti-inflammatory drug (NSAID) and triptan treatment.

The major driver for this growth will be the increased prescription of calcitonin gene-related peptide (CGRP) antagonists, gepants, and monoclonal antibodies (mAbs). In addition, the launch of five new pipeline products which will have higher annual costs of therapy (ACOTs) when compared with the cost of the most commonly used migraine treatments, will drive further growth into this market.

In order of entry, these products will include Axsome Therapeutics' AXS-07, Zosano Pharma's Qtrypta, Biohaven Pharmaceutical's zavegepant (intranasal), Satsuma Pharmaceuticals' STS101, and Biohaven Pharmaceutical's zavegepant (oral).

Key Highlights

• The prevalence of migraine is increasing in line with population growth in the 7MM.
• Oral triptans are the first-line therapy for acute migraine treatment. First-line therapies for migraine prophylaxis depend on the patients' comorbidities and include anti-epileptic agents, antidepressants, beta blockers, and angiotensin receptor blockers.
• The greatest unmet need in the migraine market is access to effective and tolerable prophylactic treatments, in addition to the need for more efficacious acute therapy options.
• The migraine pipeline is dominated by reformulations of mature products with novel delivery devices that provide preferable route of administration to patients.
• The migraine market will exhibit significant growth between 2020 and 2030, driven by the increased prescription of anti-CGRP mAbs and small molecule CGRP antagonists, gepants.

Key Questions Answered

• What are the key migraine treatments available in 2020?
• When will the late stage pipeline products launch, and how will it affect drug sales and the overall migraine market in the 7MM?
• Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Key Topics Covered:

1 Migraine: Executive Summary

1.1 Migraine Therapeutics Market will grow to $12.0B

1.2 Key Players Will Maintain Their Competitive Position

1.3 Access to Effective and Tolerable Prophylactic Treatments and Additional Acute Therapy Options Remain Unmet Needs

1.4 The Gepants Are the Most Promising New Entrants to the Migraine Market

1.5 What Do Physicians Think?

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

3.2.1 Premonitory Phase

3.2.2 Aura Phase

3.2.3 Headache Phase

3.2.4 Resolution Phase

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global and Historical Trends

4.4 7MM Forecast Methodology

4.5 Epidemiological Forecast for Migraine (2020-2030)

4.6 Discussion

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.2 Additional KOL Insights on Disease Management

6 Competitive Assessment

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Acute Therapies for Patients with, or at Risk of, Cardiovascular Disorders

7.3 Limited Acute Therapies for Patients Unresponsive to Triptan Medication

7.4 Access to Effective and Tolerable Prophylactic Treatments

7.5 Physician Education for Diagnosis

7.6 Raise Awareness of the Disease in the General Population

8 R&D Strategies

8.1 Overview

8.1.1 Gepants for Dual-Acting Acute and Preventive Indications

8.1.2 Preventive Drugs with Long Duration of Action

8.1.3 Improving Efficacy of Marketed Migraine Drugs

8.1.4 Novel MOAs

8.2 Clinical Trials Design

8.2.1 Study Design

8.2.2 Endpoints for Migraine Clinical Trials

8.2.3 Patient Recruitment

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive Assessment

10.2.1 Acute Treatment for Migraine

10.2.2 Preventive Treatment for Migraine

11 Current and Future Players

11.1 Overview

11.2 Deal-Making Trends

12 Market Outlook

12.1 Global Markets

12.1.1 Forecast

12.1.2 Drivers and Barriers - Global Issues

12.2 US

12.2.1 Forecast

12.2.2 Key Events

12.2.3 Drivers and Barriers

12.3 5EU

12.4 Japan

13 Appendix

Companies Mentioned

• AbbVie
• Amgen
• Axsome Therapeutics
• Biohaven Pharmaceuticals
• Bristol-Myers Squibb
• Currax Pharmaceuticals
• Eli Lilly
• Endo International
• Exeltis Healthcare
• GlaxoSmithKline
• H.Lundbeck
• Impel NeuroPharma
• Merck
• Novartis
• Old API Wind-down
• Pfizer
• Teva Pharmaceuticals
• Satsuma Pharmaceuticals
• Sosei Heptares
• Zosano Pharma Corp

For more information about this report visit https://www.researchandmarkets.com/r/92a1gd